Cue Biopharma, Inc. Increase (Decrease) in Accounts Payable
Cue Biopharma, Inc. (CUE) reported Increase (Decrease) in Accounts Payable of -$201.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- Cue Biopharma, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $421.00K.
- Cue Biopharma, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$622.00K, a 164.72% decline year-over-year.
- Cue Biopharma, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.60M.
- Cue Biopharma, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.28M, a 149.86% decline year-over-year.
- Cue Biopharma, Inc. increase (decrease) in accounts payable for fiscal 2025 was $1.13M.
- Cue Biopharma, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$678.00K, a 188.05% decline from fiscal 2023.
- Cue Biopharma, Inc. increase (decrease) in accounts payable for fiscal 2023 was $770.00K, a 827.71% increase from fiscal 2022.
- Cue Biopharma, Inc. increase (decrease) in accounts payable for fiscal 2022 was $83.00K, a 84.05% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $421.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$201.00K 10-Q · filed 2026-08-14 | $1.40M derived: sum of 3 quarters · filed 2026-08-14 | $120.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$622.00K 10-Q · filed 2026-05-14 | $979.00K derived: sum of 2 quarters · filed 2026-05-14 | -$301.00K derived: sum of 3 quarters · filed 2026-05-14 | -$458.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $321.00K derived: sum of 2 quarters · filed 2026-03-16 | $164.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.13M 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.44M derived: sum of 2 quarters · filed 2026-08-14 | -$476.00K 10-Q · filed 2025-11-12 | -$4.13M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $804.00K 10-Q · filed 2026-08-14 | -$2.85M derived: sum of 3 quarters · filed 2026-08-14 | -$279.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $961.00K 10-Q · filed 2026-05-14 | -$2.69M derived: sum of 2 quarters · filed 2026-05-14 | -$122.00K derived: sum of 3 quarters · filed 2026-05-14 | -$135.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.08M derived: sum of 2 quarters · filed 2026-03-16 | -$1.10M derived: sum of 3 quarters · filed 2026-03-16 | -$678.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.55M derived: sum of 2 quarters · filed 2025-11-12 | $2.97M 10-Q · filed 2025-11-12 | $3.99M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $405.00K 10-Q · filed 2025-08-12 | $1.43M derived: sum of 3 quarters · filed 2025-08-12 | $1.55M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $418.00K 10-Q · filed 2025-05-12 | $1.44M derived: sum of 2 quarters · filed 2025-05-12 | $1.56M derived: sum of 3 quarters · filed 2025-05-12 | $1.77M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.15M derived: sum of 2 quarters · filed 2025-03-31 | $1.35M derived: sum of 3 quarters · filed 2025-03-31 | $770.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $329.00K derived: sum of 2 quarters · filed 2024-11-14 | -$251.00K 10-Q · filed 2024-11-14 | $378.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $205.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$375.00K 10-Q · filed 2024-08-14 | $254.00K derived: sum of 3 quarters · filed 2024-08-14 | $731.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$580.00K 10-Q · filed 2024-05-09 | $49.00K derived: sum of 2 quarters · filed 2024-05-09 | $526.00K derived: sum of 3 quarters · filed 2024-05-09 | -$523.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $629.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.11M derived: sum of 2 quarters · filed 2024-03-28 | $57.00K derived: sum of 3 quarters · filed 2024-03-28 | $83.00K 10-K · filed 2024-03-28 | $83.11K 10-K · filed 2023-03-21 |
| 2022-09-30 | $477.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$572.00K derived: sum of 2 quarters · filed 2023-11-03 | -$546.00K 10-Q · filed 2023-11-03 | -$425.60K derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.02M 10-Q · filed 2023-08-08 | -$902.60K derived: sum of 3 quarters · filed 2023-08-08 | -$1.42M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $26.00K 10-Q · filed 2023-05-09 | $146.40K derived: sum of 2 quarters · filed 2023-05-09 | -$375.60K derived: sum of 3 quarters · filed 2023-05-09 | $343.40K derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $120.40K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$401.60K derived: sum of 2 quarters · filed 2023-03-21 | $317.40K derived: sum of 3 quarters · filed 2023-03-21 | $520.40K 10-K · filed 2023-03-21 | |
| 2021-09-30 | -$522.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $197.00K derived: sum of 2 quarters · filed 2022-11-14 | $400.00K 10-Q · filed 2022-11-14 | $916.26K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $719.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $922.00K 10-Q · filed 2022-08-04 | $1.44M derived: sum of 3 quarters · filed 2022-08-04 | $1.26M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $203.00K 10-Q · filed 2022-05-10 | $719.26K derived: sum of 2 quarters · filed 2022-05-10 | $538.26K derived: sum of 3 quarters · filed 2022-05-10 | $227.26K derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $516.26K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $335.26K derived: sum of 2 quarters · filed 2022-03-16 | $24.27K derived: sum of 3 quarters · filed 2022-03-16 | $741.26K 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$181.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$492.00K derived: sum of 2 quarters · filed 2021-11-09 | $225.00K 10-Q · filed 2021-11-09 | -$70.69K derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$311.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $406.00K 10-Q · filed 2021-08-09 | $110.31K derived: sum of 3 quarters · filed 2021-08-09 | -$1.00M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $717.00K 10-Q · filed 2021-05-10 | $421.31K derived: sum of 2 quarters · filed 2021-05-10 | -$689.69K derived: sum of 3 quarters · filed 2021-05-10 | -$1.29M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$295.69K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$1.41M derived: sum of 2 quarters · filed 2021-03-09 | -$2.01M derived: sum of 3 quarters · filed 2021-03-09 | -$1.15M 10-K · filed 2021-03-09 | |
| 2019-09-30 | -$1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$1.72M derived: sum of 2 quarters · filed 2020-11-09 | -$857.00K 10-Q · filed 2020-11-09 | $181.15K derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | -$604.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $254.00K 10-Q · filed 2020-08-07 | $1.29M derived: sum of 3 quarters · filed 2020-08-07 | $1.75M derived: sum of 4 quarters · filed 2020-08-07 | |
| 2019-03-31 | $858.00K 10-Q · filed 2020-05-07 | $1.90M derived: sum of 2 quarters · filed 2020-05-07 | $2.35M derived: sum of 3 quarters · filed 2020-05-07 | $1.63M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $1.49M derived: sum of 2 quarters · filed 2020-03-12 | $767.15K derived: sum of 3 quarters · filed 2020-03-12 | $376.15K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $453.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$271.00K derived: sum of 2 quarters · filed 2019-11-07 | -$662.00K 10-Q · filed 2019-11-07 | $37.89K derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | -$724.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$1.11M 10-Q · filed 2019-08-08 | -$415.11K derived: sum of 3 quarters · filed 2019-08-08 | -$410.11K derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | -$391.00K 10-Q · filed 2019-05-08 | $308.89K derived: sum of 2 quarters · filed 2019-05-08 | $313.89K derived: sum of 3 quarters · filed 2019-05-08 | ||
| 2017-12-31 | $699.89K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $704.89K derived: sum of 2 quarters · filed 2019-03-14 | $921.89K 10-K · filed 2019-03-14 | ||
| 2017-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $222.00K 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | $217.00K 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |